|
1
|
von Mehren M, Kane JM, Bui MM, Choy E,
Connelly M, Dry S, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, et
al: NCCN guidelines insights: soft tissue sarcoma, version 1.2021.
J Natl Compr Canc Netw. 18:1604–1612. 2020. View Article : Google Scholar
|
|
2
|
Ressing M, Wardelmann E, Hohenberger P,
Jakob J, Kasper B, Emrich K, Eberle A, Blettner M and Zeissig SR:
Strengthening health data on a rare and heterogeneous disease:
Sarcoma incidence and histological subtypes in Germany. BMC Public
Health. 18:2352018. View Article : Google Scholar
|
|
3
|
Nacev BA, Sanchez-Vega F, Smith SA,
Antonescu CR, Rosenbaum E, Shi H, Tang C, Socci ND, Rana S,
Gularte-Mérida R, et al: Clinical sequencing of soft tissue and
bone sarcomas delineates diverse genomic landscapes and potential
therapeutic targets. Nat Commun. 13:34052022. View Article : Google Scholar
|
|
4
|
Rutland CS: Advances in soft tissue and
bone sarcoma. Cancers (Basel). 16:28752024. View Article : Google Scholar
|
|
5
|
Khanna KK and Jackson SP: DNA
double-strand breaks: Signaling, repair and the cancer connection.
Nat Genet. 27:247–254. 2001. View
Article : Google Scholar
|
|
6
|
Moon J, Kitty I, Renata K, Qin S, Zhao F
and Kim W: DNA damage and its role in cancer therapeutics. Int J
Mol Sci. 24:47412023. View Article : Google Scholar
|
|
7
|
Drew Y, Zenke FT and Curtin NJ: DNA damage
response inhibitors in cancer therapy: Lessons from the past,
current status and future implications. Nat Rev Drug Discov.
24:19–39. 2025. View Article : Google Scholar
|
|
8
|
Park SH, Noh SJ, Kim KM, Bae JS, Kwon KS,
Jung SH, Kim JR, Lee H, Chung MJ, Moon WS, et al: Expression of DNA
damage response molecules PARP1, γH2AX, BRCA1, and BRCA2 predicts
poor survival of breast carcinoma patients. Trans Oncol. 8:239–249.
2015. View Article : Google Scholar
|
|
9
|
Ueno S, Sudo T and Hirasawa A: ATM:
Functions of ATM kinase and its relevance to hereditary tumors. Int
J Mol Sci. 23:5232022. View Article : Google Scholar
|
|
10
|
Akimova E, Gassner FJ, Schubert M,
Rebhandl S, Arzt C, Rauscher S, Tober V, Zaborsky N, Greil R and
Geiberger R: SAMHD1 restrains aberrant nucleotide insertions at
repair junctions generated by DNA end joining. Nucleic Acids Res.
49:2598–2608. 2021. View Article : Google Scholar
|
|
11
|
Schott K, Majer C, Bulashevska A, Childs
L, Schmidt MHH, Rajalingam Munder M and König R: SAMHD1 in cancer:
Curse or cure? J Mol Med (Berl). 100:351–372. 2022. View Article : Google Scholar
|
|
12
|
Li Y, Gao Y, Jiang X, Cheng Y, Zhang J, Xu
L, Liu X, Huang Z, Xie C and Gong Y: SAMHD1 silencing cooperates
with radiotherapy to enhance anti-tumor immunity through
IFI16-STING pathway in lung adenocarcinoma. J Transl Med.
20:6282022. View Article : Google Scholar
|
|
13
|
Zhang Z, Li P and Sun P: Expression of
SAMHD1 and its mutation on prognosis of colon cancer. Oncol Lett.
24:3032022. View Article : Google Scholar
|
|
14
|
Gutiérrez-Chamorro L, Felip E, Castellà E,
Quiroga V, Ezeonwumelu IJ, Angelats L, Esteve A, Rerez-Roca L,
Martínez-Cardús A, Fernandez PL, et al: SAMHD1 expression is a
surrogate marker of immune infiltration and determines prognosis
after neoadjuvant chemotherapy in early breast cancer. Cell Oncol
(Dordr). 47:189–208. 2024. View Article : Google Scholar
|
|
15
|
Kim KM, Moon YJ, Park SH, Park HJ, Wang
SI, Park HS, Lee H, Kwon KS, Moon WS, Lee DG, et al: Individual and
combined expression of DNA damage response molecules PARP1, γH2AX,
BRCA1, and BRCA2 predict shorter survival of soft tissue sarcoma
patients. PLoS One. 11:e01631932016. View Article : Google Scholar
|
|
16
|
Jiang H, Li C, Liu Z, Hospital S and Hu R:
Expression and relationship of SAMHD1 with other apoptotic and
autophagic genes in acute myeloid leukemia patients. Acta Haematol.
143:51–59. 2020. View Article : Google Scholar
|
|
17
|
Xun J, Ohtsuka H, Hirose K, Douchi D,
Nakayama S, Ishida M, Miura T, Ariake K, Mizuma M, Nakagawa K, et
al: Reduced expression of phosphorylated ataxia-telangiectasia
mutated gene is related to poor prognosis and gemcitabine
chemoresistance in pancreatic cancer. BMC Cancer. 23:8352023.
View Article : Google Scholar
|
|
18
|
Stucci LS, Internò V, Tucci M, Perrone M,
Mannavola F, Palmirotta R and Porta C: The ATM gene in breast
cancer: Its relevance in clinical practice. Genes (Basel).
12:7272021. View Article : Google Scholar
|
|
19
|
Schumann T, Ramon SC, Schubert N, Mayo MA,
Hega M, Maser KI, Ada SR, Sydow L, Hajikazemi M, Badstübner M, et
al: Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent
manner. J Exp Med. 220:e202208292023. View Article : Google Scholar
|
|
20
|
Savitsky K, Bar-Shira A, Gilad S, Rotman
G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, et al: A
single ataxia telangiectasia gene with a product similar to PI-3
kinase. Science. 268:1749–1753. 1995. View Article : Google Scholar
|
|
21
|
Bhandaru M, Martinka M, McElwee KJ and
Rotte A: Prognostic significance of nuclear phospho-ATM expression
in melanoma. PLoS One. 10:e01346782015. View Article : Google Scholar
|
|
22
|
Stagni V, Oropallo V, Fianco G, Antonelli
M, Cinà I and Barilà D: Tug of war between survival and death:
Exploring ATM function in cancer. Int J Mol Sci. 15:5388–5409.
2014. View Article : Google Scholar
|
|
23
|
Coquel F, Silva MJ, Técher H, Zadorozhny
K, Sharma S, Nieminuszczy J, Mettling C, Dardillac E, Barthe A,
Schmitz AL, et al: SAMHD1 acts at stalled replication forks to
prevent interferon induction. Nature. 557:57–61. 2018. View Article : Google Scholar
|
|
24
|
Daddacha W, Koyen AE, Bastien AJ, Head PE,
Dhere VR, Nabeta GN, Connolly EC, Werner E, Madden MZ, Daly MB, et
al: SAMHD1 promotes DNA end resection to facilitate DNA repair by
homologous recombination. Cell Rep. 20:1921–1935. 2017. View Article : Google Scholar
|
|
25
|
Kapoor-Vazirani P, Rath SK, Liu X, Shu Z,
Bowen NE, Chen Y, Haji-Seyed-Javadi R, Daddacha W, Minten EV,
Danelia D, et al: SAMHD1 deacetylation by SIRT1 promotes DNA end
resection by facilitating DNA binding at double-strand breaks. Nat
Commun. 13:67072022. View Article : Google Scholar
|
|
26
|
Rodríguez-Sánchez A, Quijada-Álamo M,
Pérez-Carretero C, Herrero AB, Arroyo-Barea A, Dávila-Valls J,
Rubio A, de Coca AG, Benito-Sánchez R, Rodríguez-Vicente AE, et al:
SAMHD1 dysfunction impairs DNA damage response and increases
sensitivity to PARP inhibition in chronic lymphocytic leukemia. Sci
Rep. 15:104462025. View Article : Google Scholar
|
|
27
|
World Health Organization (WHO), . Soft
tissue and bone tumours. WHO Classification of Tumours Editorial.
5th Edition. IARC Press; Lyon, France: 2020
|
|
28
|
Coindre J: Histologic grading of adult
soft tissue sarcomas. Verh Dtsch Ges Pathol. 82:59–63. 1998.
|
|
29
|
Byrd DR, Brookland RK, Washington MK,
Gershenwald JE, Compton CC, Hess KR, Sullivan DC and Jessup JM:
AJCC Cancer Staging Manual. Amin MB, Edge SB and Greene FL: Eighth
Edition. Springer; New York, USA: pp. 251–274. 2017
|
|
30
|
Clifford R, Louis T, Robbe P, Ackroyd S,
Burns A, Timbs AT, Colopy GW, Dreau H, Sigaux F, Judde JG, et al:
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and
is involved in response to DNA damage. Blood. 123:1021–1031. 2014.
View Article : Google Scholar
|
|
31
|
Chen Z, Hu J, Ying S and Xu A: Dual roles
of SAMHD1 in tumor development and chemoresistance to anticancer
drugs. Oncol Lett. 21:4512021. View Article : Google Scholar
|
|
32
|
Daddacha W, Monroe D, Schlafstein AJ,
Withers AE, Thompson EB, Danelia D, Luong NC, Sesay F, Rath SK,
Usoro ER, et al: SAMHD1 expression contributes to doxorubicin
resistance and predicts survival outcomes in diffuse large B-cell
lymphoma patients. NAR Cancer. 6:zcae0072024. View Article : Google Scholar
|
|
33
|
Xagoraris I, Vassilakopoulos TP, Drakos E,
Angelopoulou MK, Panitsas F, Herold N, Medeiros LJ, Giakoumis X,
Pangalis GA and Rassidakis GZ: Expression of the novel tumour
suppressor sterile alpha motif and HD domain-containing protein 1
is an independent adverse prognostic factor in classical Hodgkin
lymphoma. Br J Haematol. 193:488–496. 2021. View Article : Google Scholar
|
|
34
|
Bakkenist CJ and Kastan MB: DNA damage
activates ATM through intermolecular autophosphorylation and dimer
dissociation. Nature. 421:499–506. 2003. View Article : Google Scholar
|
|
35
|
Rothblum-Oviatt C, Wright J, Lefton-Greif
MA, McGrath-Morrow SA, Crawford TO and Lederman HM: Ataxia
telangiectasia: A review. Orphanet J Rare Dis. 11:1592016.
View Article : Google Scholar
|
|
36
|
Suarez F, Mahlaoui N, Canioni D,
Andriamanga C, d'Enghien CD, Brousse N, Jais JP, Fischer A, Hermine
O and Stoppa-Lyonnet D: Incidence, presentation, and prognosis of
malignancies in ataxia-telangiectasia: A report from the French
national registry of primary immune deficiencies. J Clin Oncol.
33:202–208. 2015. View Article : Google Scholar
|
|
37
|
Lee JH: Targeting the ATM pathway in
cancer: Opportunities, challenges and personalized therapeutic
strategies. Cancer Treat Rev. 129:1028082024. View Article : Google Scholar
|
|
38
|
Roossink F, Wieringa HW, Noordhuis MG, ten
Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E,
de Vries EGE, et al: The role of ATM and 53BP1 as predictive
markers in cervical cancer. Int J Cancer. 131:2056–2066. 2012.
View Article : Google Scholar
|
|
39
|
Maunakea AK, Chepelev I, Cui K and Zhao K:
Intragenic DNA methylation modulates alternative splicing by
recruiting MeCP2 to promote exon recognition. Cell Res.
23:1256–1269. 2013. View Article : Google Scholar
|
|
40
|
Ciccia A and Elledge SJ: The DNA damage
response: Making it safe to play with knives. Mol Cell. 40:179–204.
2010. View Article : Google Scholar
|
